Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.84 |
| ▸ | CDK2 | P24941 | 20/20 | 0.84 |
| ▸ | CCND1 | P24385 | 17/20 | 0.84 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.84 |
| ▸ | CDK4 | P11802 | 6/20 | 0.84 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.84 |
| ▸ | CDK9 | P50750 | 5/20 | 0.84 |
| ▸ | CCND3 | P30281 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857311 | 0.92 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL31153371 | 0.92 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857308 | 0.92 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863600 | 0.91 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857340 | 0.91 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24131191 | 0.91 | CCNE1 (0.83) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857500 | 0.91 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863598 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857417 | 0.89 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24131202 | 0.88 | CCNE1 (0.78) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |